VRTX

Vertex Pharmaceuticals (VRTX) is the lead sponsor of 28 active clinical trials listed on ClinicalTrials.gov^[4], including 16 Phase 3^[1], 9 Phase 2^[2], 7 Phase 1^[3].

Trial NCT07204275^[5] evaluates Povetacicept in Primary Membranous Nephropathy with a target enrollment of 176 participants. Trial NCT05331183^[6] evaluates ELX/TEZ/IVA in Cystic Fibrosis with a target enrollment of 297 participants. Trial NCT04786262^[7] evaluates VX-880 in Diabetes Mellitus, Type 1 with a target enrollment of 52 participants.

VRTX has 4 Form 4 insider filings recorded at the SEC in the past 30 days^[8].